Aura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors. Its proprietary platform uses virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates (VDCs). The lead candidate, bel-sar, is in late-stage clinical development for primary choroidal melanoma and other ocular oncology indications, and in early-stage development for bladder cancer. The company aims to target a range of solid tumors, including bladder cancer, by assessing the safety and efficacy of bel-sar.

Aura Biosciences is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol AURA. Its shares trade in US Dollars (USD). The company is headquartered in Boston, Massachusetts, United States, and its primary operations are in the US market.

Aura Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing novel therapies for solid tumors, leveraging its virus-like particle platform to create targeted treatments. The company's work is at the forefront of precision oncology, aiming to address unmet medical needs in ocular cancers and other solid tumors.

Aura Biosciences is headquartered in Boston, Massachusetts, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on the Nasdaq. Its clinical programs are focused on treating patients with solid tumors, with an emphasis on ocular oncology indications like primary choroidal melanoma, as well as bladder cancer. The company's therapies are developed for global markets, but its current clinical trials and regulatory activities are centered in the United States.

Aura Biosciences is a clinical-stage biotechnology company that does not yet have approved products or generate revenue from product sales. Its business model involves developing precision therapies using its proprietary virus-like drug conjugate (VDC) platform. The company advances its lead candidate, bel-sar, through clinical trials for various solid tumors, with the goal of obtaining regulatory approval and commercializing the therapy. It may also seek partnerships or licensing agreements to further develop its pipeline. Currently, the company focuses on research and development activities to bring its therapies to market.